Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins

Leukemia and Lymphoma

Volumn 49, Issue 11, 2008, Pages 2181-2186

  Giatromanolaki, Alexandra ^a   Koukourakis, Michael I ^a   Pezzella, Francesco ^b   Sivridis, Efthimios ^a   Turley, Helen ^b   Harris, Adrian L ^b   Gatter, Kevin C ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

HIF; KDR; LDH A; LDH5; Non Hodgkin lymphoma; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE 5; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; B CELL LYMPHOMA; CANCER TISSUE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOCYTE; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR VASCULARIZATION;

ANOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; ISOENZYMES; L-LACTATE DEHYDROGENASE; LYMPHOMA, B-CELL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 57049161846     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802450629     Document Type: Article

References (28)

1. Harris, A. L. (2002) Hypoxia: A key regulatory factor in tumor growth. Nat Rev Cancer, 2, pp. 38-47.
2. Holbrook, J. J., Liljas, A., Steindel, S. J. and Rossman, M. G. (1975) Lactate dehydrogenase. The Enzymes, Vol. XI, pp. 191-292. Academic Press, NY
3. Semenza, G. L., Jiang, B. H., Leung, S. W., Passantino, R., Concordet, J. P. Maire, P. et al. (1996) Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem, 271, pp. 32529-32537.
4. Koukourakis, M. I., Giatromanolaki, A. and Sivridis, E. (2003) Tumour and angiogenesis research group. Lactate dehydrogenase isoenzymes 1 and 5: Differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumor Biol, 24, pp. 199-202.
5. Boehme, V., Zeynalova, S., Kloess, M., Loeffler, M., Kaiser, U. Pfreundschuh, M. et al. (2007) German high-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol, 18, pp. 149-157.
6. Ha, C. S., Kong, J. S., McLaughlin, P., Tucker, S. L., Fayad, L. E. Hess, M. A. et al. (2003) Stage III follicular lymphoma: Long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys, 57, pp. 748-754.
7. Adida, C., Haioun, C., Gaulard, P., Lepage, E., Morel, P. Briere, J. et al. (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood, 96, pp. 1921-1925.
8. López-Guillermo, A., Cid, J., Salar, A., López, A., Montalbán, C. Castrillo, J. M. et al. (1998) Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol, 9, pp. 849-855.
9. Giatromanolaki, A., Koukourakis, M. I., Pezzella, F., Sivridis, E., Turley, H. Harris, A. L. et al. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol
10. Zaman, K., Ryu, H., Hall, D., O'Donovan, K., Lin, K. I. Miller, M. P. et al. (1999) Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-induciblefactor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci, 19, pp. 9821-9830.
11. Koukourakis, M. I., Giatromanolaki, A., Harris, A. L. and Sivridis, E. (2006) Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: A metabolic survival role for tumor-associated stroma. Cancer Res, 66, pp. 632-637.
12. Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W. Ratcliffe, P. J. et al. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol, 157, pp. 411-421.
13. Turley, H., Scott, P. A., Watts, V. M., Bicknell, R., Harris, A. L. and Gatter, K. C. (1998) Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol, 186, pp. 313-318.
14. Stewart, M., Turley, H., Cook, N., Pezzella, F., Pillai, G. Ogilvie, D. et al. (2003) The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology, 43, pp. 33-39.
15. Parums, D. V., Cordell, J. L., Micklem, K., Heryet, A. R., Gatter, K. C. and Mason, D. Y. (1990) JC70: A new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol, 43, pp. 752-757.
16. Giatromanolaki, A., Sivridis, E., Gatter, K. C., Turley, H., Harris, A. L. and Koukourakis, M. I. (2006) Tumour and Angiogenesis Research Group. Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecol Oncol, 103, pp. 912-918.
17. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Gatter, K. C. and Harris, A. L. (2006) Tumour Angiogenesis Research Group. Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway - a report of the Tumour Angiogenesis Research Group. J Clin Oncol, 24, pp. 4301-4308.
18. Giatromanolaki, A., Koukourakis, M. I., Kakolyris, S., Kaklamanis, L., Barbatis, K. O'Byrne, K. J. et al. (1998) Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer. Anticancer Res, 18, pp. 71-76.
19. Giatromanolaki, A., Koukourakis, M. I., Theodossiou, D., Barbatis, K., O'Byrne, K. Harris, A. L. et al. (1997) Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res, 3, pp. 2485-2492.
20. Koiri, R. K., Trigun, S. K., Dubey, S. K., Singh, S. and Mishra, L. (2008) Metal Cu(II) and Zn(II) bipyridyls as inhibitors of lactate dehydrogenase. Biometals, 21, pp. 117-119.
21. Major, P., Trarbach, T., Lenz, H., Kerr, D., Pendergrass, K. Douillard, J. et al. A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. J Clin Oncol
22. WHO Classification of Tumors (2001) Pathology and genetics. Tumors of Hematopoietic and Lymphoid Tissues. Lyon: IARC
23. Koster, A., van Krieken, J. H., Mackenzie, M. A., Schraders, M., Borm, G. F. van der Laak, J. A. et al. (2005) Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res, 11, pp. 154-161.
24. Ganjoo, K. N., An, C. S., Robertson, M. J., Gordon, L. I., Sen, J. A. Weisenbach, J. et al. (2006) Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma, 47, pp. 998-1005.
25. Tzankov, A., Heiss, S., Ebner, S., Sterlacci, W., Schaefer, G. Augustin, F. et al. (2007) Angiogenesis in nodal B cell lymphomas: A high throughput study. J Clin Pathol, 60, pp. 476-482.
26. Gratzinger, D., Zhao, S., Tibshirani, R. J., Hsi, E. D., Hans, C. P. Pohlman, B. et al. (2008) Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest, 88, pp. 38-47.
27. Jørgensen, J. M., Sørensen, F. B., Bendix, K., Nielsen, J. L., Olsen, M. L. Funder, A. M. et al. (2007) Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma, 48, pp. 584-595.
28. Bairey, O., Zimra, Y., Kaganovsky, E., Shaklai, M., Okon, E. and Rabizadeh, E. (2000) Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med Oncol, 17, pp. 314-318.